Variant of Uncertain Significance (VUS): Genetic Test Results and Meaning

A variant of uncertain significance, or VUS, is a DNA change for which current evidence cannot show whether it contributes to disease or is harmless. It is not a positive diagnosis, but it is not the same as a normal or negative result. The laboratory has found a real difference from the reference sequence; the uncertainty concerns its medical meaning. VUS results are common when many genes are analyzed, when the tested condition is genetically diverse, or when population and family data are limited. Most immediate healthcare decisions should not be based on a VUS alone. Instead, management is guided by the person’s symptoms, examination, family history, established clinical risk factors, and any pathogenic findings. Over time, new population data, functional studies, expert review, or family evidence may allow the laboratory to reclassify the variant. Understanding who is responsible for follow-up is therefore part of interpreting the original result.

• A VUS is an inconclusive result, not proof of a genetic disorder.
• It should not be treated like a pathogenic or likely pathogenic variant.
• Medical care usually continues according to personal and family history.
• Testing relatives can help only when planned to generate meaningful evidence.
• Variant classifications may differ among laboratories and may change over time.
• Keep the original report and maintain contact with the ordering clinic or laboratory.

Table of Contents

• Why a VUS Appears on a Report
• How Laboratories Classify Variants
• What a VUS Does Not Mean
• Evidence That Can Resolve Uncertainty
• Reclassification and Follow-Up
• Medical and Family Decisions With a VUS
• Questions to Ask About Your Result

Why a VUS Appears on a Report

Every person’s DNA differs from the reference genome at millions of positions. Most differences are benign. A small proportion are known to cause disease, and many rare changes have not been studied enough to place confidently in either category. When a clinically tested variant falls into that evidence gap, the laboratory may classify it as a VUS.

Uncertainty can arise for several reasons. The variant may be absent or extremely rare in population databases, leaving too few observations to judge whether healthy people carry it. It may change an amino acid without a known effect on protein function. Computer models may disagree. A laboratory study may suggest altered function but may not accurately represent the human organ or disease. Published cases may be few, poorly described, or affected by other genetic explanations.

A VUS is more likely when a test examines many genes. A focused familial-variant test asks whether one established pathogenic change is present. A broad panel, exome, or genome scans far more DNA, increasing the chance of finding rare changes with limited evidence. This is one reason a larger test does not always create a clearer answer.

Ancestry representation also matters. Variant databases have historically contained more data from some populations than others. A change may appear rare simply because people with a particular ancestry have been underrepresented. With better sampling, a variant once thought suspicious may prove too common among healthy people to cause a rare, highly penetrant disorder.

The gene–disease relationship itself may be uncertain. A laboratory should not assume that every variant in a gene named in a publication explains a patient’s condition. Evidence must support both that the gene causes the disease and that the specific variant disrupts the gene in the relevant way.

A VUS can be found in diagnostic, carrier, predictive, prenatal, cardiac, neurologic, cancer-risk, ophthalmic, renal, metabolic, and other testing. Its implications depend on context. In a person with symptoms, it may be a candidate explanation but remains unproven. In a healthy person, it should not be used to predict future disease. In recessive testing, one pathogenic variant plus one VUS does not automatically establish that both gene copies are disease-causing.

Somatic tumor testing also uses uncertainty categories, but tumor actionability and germline disease classification are different frameworks. A tumor VUS should not be assumed to represent an inherited risk, and a germline VUS should not be treated as a cancer treatment target.

How Laboratories Classify Variants

Clinical laboratories commonly use a five-category system for germline sequence variants: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. Classification combines independent lines of evidence rather than relying on one database entry or one computer prediction.

Population evidence asks how often the variant occurs in people without the relevant disease. A variant that is common in the general population is unlikely to cause a very rare, highly penetrant disorder. Frequency thresholds must match the disease prevalence, inheritance pattern, penetrance, and genetic heterogeneity.

Case evidence considers whether the variant has been observed in people with a consistent phenotype. The number and quality of cases matter. Repeated publication of the same family is not equivalent to independent observations.

Segregation evidence examines whether the variant tracks with disease across relatives. A change present in multiple clearly affected relatives and absent from unaffected older relatives may support pathogenicity. Segregation can mislead in small families, reduced-penetrance conditions, or disorders with common phenocopies.

De novo evidence assesses whether the variant arose in an affected person and is absent from both parents. Confirmation of biological relationships and accurate parental testing strengthens this evidence. De novo status is more persuasive for a gene and phenotype known to follow that mechanism.

Functional evidence evaluates whether the variant changes RNA splicing, protein activity, cellular localization, expression, or another relevant process. A well-validated assay that reflects disease biology carries more weight than a research experiment with uncertain clinical relevance.

Computational evidence predicts effects on protein sequence, conservation, or splicing. These tools are supportive, not definitive. Many algorithms use overlapping training data and should not be counted as fully independent evidence.

Variant type and location can be important. A premature stop variant may be pathogenic in a gene where loss of function causes disease, but not in a gene where disease requires a specific gain-of-function mechanism. A missense change in a critical functional domain may be more suspicious than one in a tolerant region.

Phenotype specificity asks whether the person’s features strongly match the known gene-associated condition. A good fit supports interpretation but cannot transform an otherwise unsupported change into a pathogenic variant.

The American College of Medical Genetics and Genomics and Association for Molecular Pathology framework provides standard terminology, while ClinGen expert groups refine criteria for particular genes and disorders. Gene-specific rules matter because the same evidence has different weight across diseases.

Laboratories can reach different classifications because they have different internal cases, use different transcripts, apply evidence at different dates, or weigh data differently. A conflict does not mean the DNA changed; it means the evidence was interpreted differently. Expert-panel classifications and transparent reasoning can help resolve discrepancies.

What a VUS Does Not Mean

The safest starting point is to remove conclusions that the result cannot support.

A VUS does not confirm that a person has a genetic condition. Even when the gene seems plausible and the symptoms fit, the variant has not met the threshold for disease causation. The clinical diagnosis may still be valid on other grounds, but the VUS is not molecular confirmation.

A VUS does not prove increased future risk. An unaffected person should not be told that disease is expected, that cancer risk is elevated, or that sudden cardiac death is likely solely because of an uncertain variant.

A VUS does not usually justify irreversible intervention. Preventive surgery, device implantation, pregnancy termination, organ removal, or other major decisions should not rest on an uncertain classification alone. The person may have separate clinical indications for an intervention, but those should be stated independently.

A VUS does not establish carrier status in the same way as a pathogenic variant. In recessive conditions, a person with one VUS may or may not carry a disease-causing allele. Partner testing and reproductive risk calculations should not assume pathogenicity.

A VUS does not explain every symptom simply because it was the only finding. Broad testing often returns uncertain changes unrelated to the reason for testing. “Something was found” can feel more meaningful than a negative result, but rarity is not the same as causality.

A VUS does not mean the laboratory made a mistake. Uncertainty is an honest scientific category used when available data do not justify either a harmful or harmless classification. Forcing a binary answer would create false diagnoses or false reassurance.

A VUS is also not necessarily permanent. It can later be downgraded to likely benign or benign, upgraded to likely pathogenic or pathogenic, remain uncertain, or occasionally be interpreted differently for another disorder. The result’s wording should always include the gene, exact variant, condition, and date.

Patients sometimes encounter online claims that a variant is “disease-causing” because it appears in a research paper, commercial interpretation tool, or community database. These sources can be useful leads but may use outdated classifications, unverified submissions, or evidence not appropriate for clinical decisions. Raw-data interpretations are especially vulnerable to technical error and missing context.

The practical rule is simple: until a qualified clinical laboratory reclassifies the variant or a genetics team establishes another evidence-based conclusion, do not manage it as a positive result. This aligns with the broader principles used to interpret pathogenic, benign, and VUS classifications.

Evidence That Can Resolve Uncertainty

Not every VUS can or should trigger additional testing. Follow-up is most useful when a specific study could add evidence that changes classification.

Testing affected relatives may show whether the variant is present in family members with the same condition. If several clearly affected relatives do not carry it, the variant is less likely to explain the familial disease. If it tracks consistently, that may support pathogenicity. The family structure must be informative enough for the result to matter.

Testing parents can establish whether a variant is de novo or inherited. In a child with a severe dominant developmental disorder, a confirmed de novo variant may provide important evidence. Inheriting the variant from a healthy parent can support a benign interpretation, but not always; reduced penetrance, mild features, mosaicism, age-related onset, and variable expressivity must be considered.

Determining phase can help in recessive disease. When two variants are found in one gene, parental testing may show whether they are in trans on opposite gene copies or in cis on the same copy. Two variants in cis leave the other gene copy unaffected and generally do not satisfy a recessive diagnosis. Even in trans, a VUS remains uncertain unless other evidence supports pathogenicity.

Detailed phenotyping can strengthen or weaken the gene match. Specialist examination, imaging, biochemical studies, pathology, electrophysiology, or standardized clinical measurements may reveal a characteristic pattern. Conversely, a major mismatch may suggest that another gene or nongenetic condition should be investigated.

RNA analysis may determine whether a variant disrupts splicing. The correct tissue is important because a gene may not be expressed in blood. A well-designed assay can sometimes move a splice-region VUS toward pathogenic or benign classification.

Functional studies can test protein activity or cellular effects. Clinical laboratories typically require evidence that the assay is validated, reproducible, and relevant to the disease mechanism. A custom research experiment may be informative but is not automatically sufficient for reclassification.

Population data often accumulate without any action by the patient. If the variant is later observed frequently in healthy people, it may be downgraded. Conversely, repeated observation in well-characterized affected individuals can add pathogenic evidence.

Expert-panel review can harmonize criteria for a particular gene. ClinGen Variant Curation Expert Panels evaluate evidence using gene-specific rules and may resolve conflicting laboratory submissions.

Family testing should be coordinated through the ordering laboratory or genetics clinic. Testing every relative privately can generate uninterpretable results, reveal unexpected family relationships, and create cost without contributing useful evidence. The goal is not to see who else “has the VUS”; it is to answer a defined classification question.

Reclassification and Follow-Up

Reclassification occurs when new evidence changes the category assigned to a variant. Large laboratory studies show that reclassification is a normal part of genomic medicine, and most VUS changes are downgrades toward likely benign or benign rather than upgrades. That pattern makes sense: rare variants initially lack population data, then prove compatible with health as more people are tested.

An upgrade can occur when multiple affected cases, convincing segregation, validated functional data, or gene-specific expert review establish disease causation. If a VUS becomes pathogenic or likely pathogenic, the result may then affect diagnosis, surveillance, treatment, reproductive counseling, and targeted testing of relatives.

A downgrade means the variant should no longer be considered a candidate disease explanation. It does not erase a person’s symptoms or family history. Clinical evaluation may still be needed, and another genetic cause may remain undiscovered.

There is no universal schedule for reanalysis. Laboratories differ in whether they continuously review variants, issue amended reports, contact the ordering clinician, or expect a new request. Some update only when significant evidence comes to their attention. Clinics also differ in their ability to track patients over many years.

Before relying on future notification, ask:

• Does the laboratory automatically issue amended reports?
• Who receives the update—the patient, ordering clinician, or both?
• Is the clinic responsible for requesting reinterpretation?
• How should contact information be updated?
• When would a formal reanalysis be reasonable?
• Is there a fee for reanalysis or family studies?

Keep the original report rather than only the gene name. Exact DNA and protein notation, transcript, genome build, zygosity, laboratory, accession number, and classification date are essential. Similar variants can have very different meanings.

A patient may check a public database such as ClinVar, but public entries are not a substitute for an amended clinical report. Submissions may conflict, use different conditions, or be older than an expert review. Discuss apparent changes with the ordering genetics team.

Recontact is especially important when the person’s phenotype changes, another relative receives a genetic diagnosis, new affected relatives become available for testing, pregnancy is planned, or the result could alter urgent management if upgraded.

Broader test reanalysis may find a different diagnosis even if the original VUS remains uncertain. New gene–disease discoveries and improved pipelines can reveal variants that were previously filtered or not interpretable. This is particularly relevant after whole-exome sequencing or genome sequencing.

Medical and Family Decisions With a VUS

A VUS should not create a vacuum in care. The appropriate plan is based on evidence that exists outside the uncertain variant.

For someone with symptoms, clinicians continue the diagnostic evaluation and treat the clinical condition. A child with seizures still receives neurologic care; a person with cardiomyopathy still follows cardiac surveillance; a patient with cancer still receives management based on personal and family risk. The VUS may be revisited, but it should not delay necessary treatment.

For hereditary cancer testing, screening and prevention should follow the person’s cancer history, pedigree, pathology, and established risk models. Relatives should not undergo predictive testing for a VUS as though it were the family’s pathogenic variant. If a family clearly meets high-risk criteria, enhanced screening may be appropriate regardless of the inconclusive genetic result.

For cardiac conditions, implantable devices, sports restrictions, or medication should be guided by phenotype and accepted clinical risk factors. Genotype-specific management requires a pathogenic or likely pathogenic finding with a valid gene–disease association.

For reproductive planning, a VUS creates uncertainty rather than a defined recurrence risk. Prenatal diagnosis or preimplantation genetic testing directed solely at a VUS is generally problematic because selecting against the variant assumes it causes disease. A genetics professional can assess whether another pathogenic result, biochemical diagnosis, or family-based evidence provides a clearer basis.

Communicating the result to relatives requires careful wording. A useful message is: “A DNA change was found, but the laboratory does not currently know whether it affects health. It should not be used as a predictive family test unless the genetics team recommends a specific study.” This avoids both alarm and dismissal.

Insurance and medical records can also be affected by careless labels. The problem list should not convert “VUS in gene X” into “gene X syndrome” unless a clinical diagnosis exists independently. Accurate documentation preserves the uncertainty and prevents future clinicians from treating the variant as proven.

Emotionally, a VUS can be frustrating because it replaces one uncertainty with another. Some people feel compelled to research continuously or attribute every symptom to the finding. A genetic counselor can help separate what is known, what is possible, and what remains unsupported.

The most protective approach is proportionality: do not ignore relevant clinical risk, but do not allow an uncertain laboratory finding to outweigh established medical evidence.

Questions to Ask About Your Result

Start by asking why the variant was reported. Is it in a gene definitively associated with the person’s condition? Does the phenotype fit? Was it the only finding, one of several, or a secondary result unrelated to the testing indication?

Then review the evidence behind the classification:

1. What exact variant and transcript are listed?
2. Which condition was used for interpretation?
3. Is the variant absent, rare, or common in population databases?
4. Has it been seen in affected or healthy people?
5. Do functional or RNA studies exist?
6. Are classifications from other clinical laboratories or expert panels available?
7. Does the laboratory use gene-specific criteria?

Ask what the result changes today. In many cases the answer should be “nothing based on the VUS alone.” The clinician should state which surveillance, treatment, or screening recommendations come from symptoms or family history rather than from the variant.

Ask whether family studies would be informative. Identify the best relatives before anyone is tested. An affected relative is often more useful than a healthy relative. The laboratory may offer no-cost or reduced-cost studies when results could help classification, but such programs have eligibility rules and may not return independent clinical reports.

Clarify follow-up responsibility. Record the laboratory’s name, report date, ordering clinic, and contact method. Put a reminder to reconnect at an agreed interval or after a major family event. Do not assume an automated message will arrive years later.

If another laboratory calls the same variant pathogenic or benign, request professional reconciliation. Differences may reflect newer evidence, condition-specific interpretation, transcript choice, or a true classification conflict. A genetics professional can ask the laboratories to review each other’s evidence.

When testing was ordered through a consumer or low-contact service, consider confirmation and interpretation through a clinical genetics setting. The original call may be technically incorrect, based on a limited platform, or missing phenotype information.

Finally, ask whether the diagnostic strategy should move forward. A VUS may coexist with an unrecognized cause. Additional testing, reanalysis, specialist evaluation, or clinical follow-up may be more useful than concentrating on the uncertain change. The purpose of the report is to improve care—not to make the VUS the center of every future decision.

References

1. ACMG Points to Consider for Reporting Variants of Uncertain Significance in Germline Testing
2. ClinGen Variant Classification Guidance
3. Clinical Variant Reclassification in Hereditary Disease Genetic Testing
4. Reclassification of BRCA1 and BRCA2 Variants of Uncertain Significance
5. National Human Genome Research Institute: Variant of Uncertain Significance
6. ACMG/AMP Standards and Guidelines for Sequence Variant Interpretation

Disclaimer

This article provides general educational information and does not replace interpretation by a qualified genetics professional or advice from the healthcare team managing the relevant condition. A VUS should not be used by itself to diagnose disease, estimate a relative’s risk, or justify major medical or reproductive decisions. Classification and management can change as evidence develops, so follow-up should be based on the exact laboratory report.